Journal of Clinical Oncology
Articles in this Issue
Cardiovascular toxicity of second-generation TKIs versus imatinib in first-line chronic myeloid leukemia: An updated systematic review and meta-analysis.
e18604 Background: BCR–ABL1 tyrosine kinase inhibitors (TKIs) are the standard first-line therapy for chronic myeloid leuk...
Financial toxicity, self-efficacy, self-care, and health-related quality of life in gastrointestinal cancer survivors in Taiwan.
e23273 Background: Gastrointestinal cancer survivors frequently experience symptom burden, psychological adjustment demand...
National trends and inpatient outcomes of invasive aspergillosis in hospitalizations with hematologic malignancies: A 2020-2022 National Inpatient Sample analysis.
e18519 Background: Invasive aspergillosis is a severe opportunistic fungal infection affecting immunocompromised patients,...
Application of locally developed referral criteria for palliative care in metastatic hormone receptor–positive breast cancer patients: A non-randomized controlled trial.
e24080 Background: Persons with advanced cancer are often referred to palliative care in the late stages of their disease....
Dynamic changes in immune checkpoint and cell populations following lymphodepletion and CAR-T therapy in hematologic malignancies.
7542 Background: Chimeric antigen receptor T-cell (CAR-T) therapy has significantly improved outcomes in relapsed and refr...
Bytes to blood: Artificial intelligence in leukemia management—A 2025 update.
e18557 Background: Artificial intelligence (AI) has been proposed as a tool to aid in the diagnosis, treatment, and monito...
Barriers and enablers to pediatric palliative care integration in low- and middle-income countries: A systematic review and meta-synthesis.
10055 Background: Globally around 21 million children require pediatric palliative care yearly of whom more than 97-98% of...
Multicenter phase 2 study of hydroxychloroquine (HCQ) and chlorphenesin carbamate (CPC) in combination with mFOLFIRINOX in patients with advanced pancreatic adenocarcinoma (PDAC).
4189 Background: PDAC is one of the most lethal malignancies, with most patients (pts) presenting with advanced disease. A...
Development of a novel blood-based translational PCR screen for monoclonal B-cell lymphocytosis.
e19033 Background: Over 10 million Americans have monoclonal B-cell lymphocytosis (MBL), a precursor to CLL, with age-asso...
Fovinaciclib versus placebo combined with fulvestrant for advanced breast cancer after endocrine therapy: A randomized, double-blind phase 3 trial.
1101 Background: Approximately 70% breast cancer (BC) patients have hormone receptor (HR)-positive and human epidermal gro...
Safety and efficacy of ifebemtinib combined with garsorasib in KRAS G12C mutant colorectal cancer from a randomized part of a phase Ib/II study.
3591 Background: Studies (Yaeger R, et al.; Fakih, MG, et al.) have shown when RASi is combined with optimal therapeutic p...
Post-COVID changes to healthcare utilization, expenditures, and care prioritization among US cancer survivors.
e23131 Background: The COVID-19 pandemic disrupted cancer care delivery, leading to adaptations. We examined cost burden (...
Hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 inhibitors as first-line treatment for hepatocellular carcinoma with high tumor burden and portal vein tumor thrombus: A target trial emulation study (CHANCE 2416).
4132 Background: Patients with advanced hepatocellular carcinoma (HCC) characterized by high tumor burden (beyond up-to-se...
Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) in patients (pts) with previously treated locally advanced/metastatic urothelial carcinoma (la/mUC).
4566 Background: Zele is a highly selective Bicycle Drug Conjugate (BDC) targeting Nectin-4, a protein overexpressed in la...
Mechanism-driven comparative safety signals of capivasertib versus CDK4/6 inhibitors: A FAERS pharmacovigilance study.
e23444 Background: Capivasertib, a first-in-class AKT inhibitor approved for hormone receptor-positive/human epidermal gro...
Phase 3, multicenter, randomized, controlled open-label study: Efficacy and safety of M701 (EpCAM×CD3 bispecific antibody) intraperitoneal infusion in advanced epithelial solid tumor with malignant ascites vs paracentesis.
104 Background: Malignant ascites (MA) is a severe complication of advanced epithelial cancers, imposing a heavy symptom b...
Real-world association between the androgen receptor gene polymorphisms (CAG repeats) and aggressiveness of prostate cancer at diagnosis in the Medstar Health Network.
e17143 Background: Clinical manifestations of prostate cancer (PC) range from indolent to aggressive disease. Androgen rec...
Hybrid AI framework for automated prostate cancer disease state ascertainment from real-world electronic health records.
e17003 Background: Accurate ascertainment of prostate cancer (PCa) disease states—biochemical recurrence (BCR), castration...
First 1000 patients report of global practice patterns and clinical outcomes in the Collaborative Ocular Melanoma Natural History (OMNi) real-world database (NCT04588662).
9595 Background: OMNi (NCT04588662) is an ambispective natural history database developed to provide contemporary real-wor...
The quantum scalpel: Unveiling new dimensions in cancer therapy.
e15000 Background: The Cell Memory Disc (CMD) model describes each human cell as a quantum wave–particle system co...
Clinical characteristics and outcomes of germline and sporadic NF1-associated gastrointestinal stromal tumors: Insights from a real-world patient registry.
11538 Background: Neurofibromatosis type 1 (NF1)-associated gastrointestinal stromal tumor (GIST) is a rare, distinct mole...
Assessment of gedatolisib (geda) pharmacokinetics (PK), drug-drug interactions (DDI), and exposure-safety and exposure-efficacy relationships.
e13069 Background: Gedatolisib is a highly potent, multitarget PI3K/AKT/mTOR (PAM) inhibitor that targets all class I PI3K...
Mid-treatment circulating tumor HPV DNA to guide early radiotherapy cessation in HPV-associated oropharyngeal cancer.
e18054 Background: Circulating tumor HPV DNA (ctHPVDNA) is an emerging biomarker in HPV-associated oropharyngeal squamous...
Biology-driven lead-time considerations for endocrine therapy de-escalation in elderly patients with favorable breast cancer.
e12726 Background: Small breast cancers are generally assumed to have a favorable prognosis because of their limited size....
Genomically personalized radiation dose de-escalation: A phase II basket radiation study in patients with pathogenic mutations in <i>ATM</i> .
3015 Background: ATM (ataxia-telangiectasia mutated) is a key DNA damage response gene, and pathogenic...